RPRX | Royalty pharma plc - Stock Value & PE Ratio Analysis

3

24

15

Good Growth

AI analysis rates RPRX with a higher value score of 4.
It is mainly due to adequate operating cash flow, along with adequate safety shown in the balance sheet.
Over the past 3 months, RPRX has maintained a consecutive value rating of 4.0, higher than the rating of 2.3 over the past 3 years, indicating noticeable improvement in enterprise value.
Compared to all stocks in the Health Care sector, RPRX has a higher value rating.

RPRX Value Reference Factors

The Value score is derived from various data and factor information, integrated through AI algorithms. The following factors are part of the evaluation used by AI value scores.

Update to 2025/02/21 (Weekly Update)

RPRX Financial Forecast

Unit : USD

Update to 2025/5/4 (Quarterly Update)

RPRX Earnings Table

Unit : USD

QTR	Non-GAAP EPS	EPS YoY	EPS Surprise %	Sales	Sales YoY	Sales Surprise %	NPM
Current	1.04	31.6%	12.1%	564.69M	5.3%	-19%	19%
2024Q1	0.96	12.9%	-0.5%	537.27M	-0.2%	-14.4%	0.8%
2023Q4	0.98	-38.8%	-0.7%	567.98M	-17%	-14.7%	82.9%
2023Q3	1.15	-26.3%	13.9%	596M	5.3%	-11.5%	13.4%
2023Q2	0.79	8.2%	-2.5%	536.31M	-6.5%	-12.7%	42.3%

Update to 2025/5/9 (Quarterly Update)

RPRX Historical Value Score

You can use historical scores of 3 or above to observe potential performance and make investment decisions.

RPRX Value Strategy Backtest

The following backtest is based on specified rules since 2007. Price chart shows buy/sell time, cumulative returns, and backtesting statistics.

Entry

Exit

The Backtest Result of RPRX from 2020/06 till Now

13.36%
Cumulative Return: 2.60%
Annual Return: 14.54%
Volatility: 0.18
Sharpe Ratio

Statistics data for entering at or above a Value score of 4 and exiting at or below a Value score of 2 from June, 2020 to May, 2025. (Total Trades: 1)